<?xml version="1.0" encoding="UTF-8"?>
<ref id="B22-pharmaceuticals-13-00233">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zhao</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Zang</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Lan</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liao</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Repurposing an antidandruff agent to treating cancer: Zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases</article-title>
  <source>Oncotarget</source>
  <year>2017</year>
  <volume>8</volume>
  <fpage>13942</fpage>
  <lpage>13956</lpage>
  <pub-id pub-id-type="doi">10.18632/oncotarget.14572</pub-id>
  <pub-id pub-id-type="pmid">28086217</pub-id>
 </element-citation>
</ref>
